At the news
? NEUTRALIMPACT 4/10 8-K filed Nov 12, 2026 at 17:01 ET
Praxis Precision Medicines hosted an Investor Day on November 12, 2026, presenting commercial launch plans for two upcoming PDUFA dates in late 2026/early 2027 (relutrigine for SCN2A/SCN8A DEE and ulixacaltamide for essential tremor), updated clinical data including 86% seizure reduction at 18 months for relutrigine and positive FDA sensitivity analyses for ulixacaltamide, and an expanded pipeline across movement disorders, pain, epilepsy, and antisense oligonucleotide programs. The filing is a routine business update with no financial results; all revenue projections are analyst consensus or illustrative scenarios, not company guidance.
- Relutrigine PDUFA date December 27, 2026 for SCN2A/SCN8A DEE; ulixacaltamide PDUFA date January 29, 2027 for essential tremor
- Updated relutrigine open-label extension data showed 86% reduction in motor seizures from baseline at 18 months
- Ulixacaltamide ESSENTIAL3 sensitivity analyses requested by FDA were consistent with primary result; 95-week long-term safety data showed durable ADL improvement
- Company plans to initiate ulixacaltamide studies in Parkinson's disease, restless legs syndrome and autism spectrum disorder in 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access